Axcella Health Inc. (NASDAQ:AXLA) – Stock analysts at Wedbush increased their FY2022 earnings per share (EPS) estimates for shares of Axcella Health in a research report issued to clients and investors on Wednesday, January 12th. Wedbush analyst L. Moussatos now forecasts that the company will earn ($1.75) per share for the year, up from their previous forecast of ($1.76).
Several other equities research analysts also recently weighed in on AXLA. The Goldman Sachs Group downgraded shares of Axcella Health from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $9.00 to $5.00 in a research note on Wednesday, September 22nd. Roth Capital reiterated a “buy” rating on shares of Axcella Health in a research note on Thursday, December 16th. Chardan Capital increased their target price on shares of Axcella Health from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, November 16th. Noble Financial assumed coverage on shares of Axcella Health in a research note on Tuesday, October 12th. They set an “outperform” rating and a $6.00 target price for the company. Finally, Zacks Investment Research upgraded shares of Axcella Health from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Axcella Health has a consensus rating of “Buy” and a consensus price target of $8.61.
Axcella Health (NASDAQ:AXLA) last released its quarterly earnings data on Wednesday, November 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04.
A number of institutional investors have recently modified their holdings of AXLA. Renaissance Technologies LLC increased its holdings in Axcella Health by 129.0% in the second quarter. Renaissance Technologies LLC now owns 158,202 shares of the company’s stock valued at $634,000 after buying an additional 89,115 shares in the last quarter. Millennium Management LLC increased its holdings in Axcella Health by 579.6% in the second quarter. Millennium Management LLC now owns 92,688 shares of the company’s stock valued at $372,000 after buying an additional 79,049 shares in the last quarter. Ergoteles LLC purchased a new position in Axcella Health in the second quarter valued at about $257,000. Edgewood Management LLC purchased a new position in Axcella Health in the second quarter valued at about $100,000. Finally, Marshall Wace LLP increased its holdings in Axcella Health by 31.4% in the second quarter. Marshall Wace LLP now owns 72,422 shares of the company’s stock valued at $290,000 after buying an additional 17,287 shares in the last quarter. 61.75% of the stock is owned by institutional investors.
Axcella Health Company Profile
Axcella Health, Inc is a biotechnology company. It engages in the research and development of treatment for diseases and improve health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy; and AXA1125, for non-alcoholic steatohepatitis.
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.